ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Return on equity 2016–2025
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-0.3%FY2025 · since FY2016: -85.5% → -0.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -0.3% | +322.9 pp |
| FY2024 | -323.3% | -247.6 pp |
| FY2023 | -75.7% | -31.5 pp |
| FY2022 | -44.2% | -9.7 pp |
| FY2021 | -34.5% | -16.1 pp |
| FY2020 | -18.3% | -46.1 pp |
| FY2019 | 27.8% | +84.6 pp |
| FY2018 | -56.8% | -14.6 pp |
| FY2017 | -42.2% | +43.3 pp |
| FY2016 | -85.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice